To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden

Completed · Phase 2

Conditions studied: Alzheimer's Disease

In brief

The purpose of this study is to compare PET measurements of fibrillar amyloid burden using \[18F\]AZD4694.

Key facts

Study ID

NCT00991419

Run by

AstraZeneca

People needed

25

Starts

2010-02-01

Expected to finish

2011-08-01

Last updated by the study team

2013-01-30

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female, of any race or/ethnicity
• ECG, vital signs, and clinical laboratory values are within normal limits at enrollment or deemed not clinically significant by the physician

You may not qualify if…

• Significant recent (within 6 months) history of neurological (including stroke) or psychiatric disorder or substance abuse
• Participated in a PET study within the last 12 months
• Pregnancy or lactation

Where it is running

• Research Site — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.